The Center for Neurologic Study Website is designed to present our current activities. The Center, a non profit 501C3 corporation, was founded in 1979 with the intent of helping patients and families who have been affected by presently incurable neurologic disease. To accomplish this, the Center focuses on experimental treatment and patient/family support and education. Along with others CNS was instrumental in the development of Interferon as a treatment modality. This is now one of the standard therapies for multiple sclerosis. And CNS has been a leader in an area now referred to as Translational Medicine. For example, the Center was the first to test a growth factor as a potential treatment for ALS.
And we continue to work at the forefront of neurological therapy. Toward this end we collaborate with biotech companies and universities in an effort to develop cutting edge therapies for neurologic disorders. Most recently we are involved in the development of antisense molecules that could represent a major opportunity to treat heritable diseases of the nervous system such as familial amyotrophic lateral sclerosis and Huntingtons disease. Recently this work was recognized by the ALS Association that awarded Dr. Don Cleveland/UCSD, Frank Bennett/Isis Pharmaceuticals, and I with an Essey award (see News).
The seminal discovery of DMQ at CNS resulted in the award of 5 U.S. patents. This drug combination was ultimately formulated by Avanir pharmaceutical corporation, leading to a product that is now called Nuedexta. In clinical trials the drug was demonstrated to be highly effective for the treatment of emotional lability that occurs in association with neurological conditions, such as amyotrophic lateral sclerosis and multiple sclerosis. In October of 2010 the drug was approved by the Food and Drug Administration for sale in the United States. And in 2013, the drug was approved in the European Union. Currently, Nuedexta being tested for its effect on behavior in persons with Alzheimer's disease, and the ALS association has awarded CNS a grant to study the effect of the drug on speech and swallowing in patients with ALS. This study is being conducted at 7 academic centers. The Northeast ALS consortium (NEALS) is managing the trial. The first patient was enrolled in May, 2013 and as of June 2014, 48 subjects have been enrolled. It is anticipated that the results of this study will be available by the end of the year.
Our website is the latest in a long standing effort to provide patient/family education and support. Beginning in 1979, CNS sponsored one of the first neurologically-based educational programs. Individual counseling is available to patients who visit the Center and through our website we provide information that we hope will be useful. In special circumstances, the Center provides counseling to patients through the internet.
Our success is due, in part, to the support we have received from individuals, corporations and foundations. We welcome the opportunity to discuss how your support will advance the treatment of presently incurable diseases such as Amyotrophic Lateral Sclerosis and kindred disorders.